Technical Analysis for GRAY - Graybug Vision, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Historical GRAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Support | Bullish | 6.15% | |
| Expansion Breakout | Bullish Swing Setup | 6.15% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 6.15% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Reversed from Down | 3 days ago |
| Down 5% | 3 days ago |
| Down 1 ATR | 3 days ago |
| Down 3% | 3 days ago |
| Down 2 % | 3 days ago |
Get a Trading Sidekick!
- Earnings date: ???
Graybug Vision, Inc. Description
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Diseases Macular Degeneration Ophthalmology Related Macular Degeneration Retina Glaucoma Nerve Diabetic Retinopathy Macular Edema Blindness Wet Age Related Macular Degeneration Diabetic Macular Edema Retinopathy Intravitreal Administration Macula Of Retina Intravitreal Injection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.88 |
| 52 Week Low | 3.43 |
| Average Volume | 1,521,481 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 4.53 |
| 20-Day Moving Average | 4.13 |
| 10-Day Moving Average | 4.59 |
| Average True Range | 0.62 |
| ADX | 36.98 |
| +DI | 39.84 |
| -DI | 7.87 |
| Chandelier Exit (Long, 3 ATRs) | 5.12 |
| Chandelier Exit (Short, 3 ATRs) | 5.28 |
| Upper Bollinger Bands | 5.40 |
| Lower Bollinger Band | 2.87 |
| Percent B (%b) | 1.19 |
| BandWidth | 61.07 |
| MACD Line | 0.10 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 0.2931 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.83 | ||||
| Resistance 3 (R3) | 8.86 | 7.92 | 8.33 | ||
| Resistance 2 (R2) | 7.92 | 7.16 | 7.90 | 8.17 | |
| Resistance 1 (R1) | 6.89 | 6.70 | 6.42 | 6.86 | 8.00 |
| Pivot Point | 5.95 | 5.95 | 5.71 | 5.93 | 5.95 |
| Support 1 (S1) | 4.92 | 5.19 | 4.45 | 4.89 | 3.74 |
| Support 2 (S2) | 3.98 | 4.73 | 3.96 | 3.57 | |
| Support 3 (S3) | 2.95 | 3.98 | 3.41 | ||
| Support 4 (S4) | 2.92 |
